Abstract:BackgroundIt is now understood that APOBEC3 family proteins (A3s) are essential in tumor progression, yet their involvement in tumor immunity and stemness across diverse cancer types remains poorly understood.MethodsIn the present study, comprehensive genome-wide statistical and bioinformatic analyses were conducted to elucidate A3 family expression patterns, establishing clinically relevant correlations with prognosis, the tumor microenvironment(TME), immune infiltration, checkpoint blockade, and stemness across cancers. Different experimental techniques were applied, including RT-qPCR, immunohistochemistry, sphere formation assays, Transwell migration assays, and wound-healing assays, to investigate the impact of A3C on low-grade glioma (LGG) and glioblastoma multiforme (GBM), as well as its function in glioma stem cells(GSCs).ResultsDysregulated expression of A3s was observed in various human cancer tissues. The prognostic value of A3 expression differed across cancer types, with a link to particularly unfavorable outcomes in gliomas. A3s are associated with the the TME and stemness in multiple cancers. Additionally, we developed an independent prognostic model based on A3s expression, which may be an independent prognostic factor for OS in patients with glioma. Subsequent validation underscored a strong association between elevated A3C expression and adverse prognostic outcomes, higher tumor grades, and unfavorable histology in glioma. A potential connection between A3C and glioma progression was established. Notably, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses implicated A3C in immune system-related diseases, with heightened A3C levels contributing to an immunosuppressive tumor microenvironment (TME) in glioma. Furthermore, in vitro experiments substantiated the role of A3C in sustaining and renewing glioma stem cells, as A3C deletion led to diminished proliferation, invasion, and migration of glioma cells.ConclusionThe A3 family exhibits heterogeneous expression across various cancer types, with its expression profile serving as a predictive marker for overall survival in glioma patients. A3C emerges as a regulator of glioma progression, exerting its influence through modulation of the tumor microenvironment and regulation of stemness.

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas

Upregulation of the APOBEC3 Family is Associated with a Poor Prognosis and Influences Treatment Response to Raf Inhibitors in Low Grade Glioma

The Role of APOBEC3C in Modulating the Tumor Microenvironment and Stemness Properties of Glioma: Evidence from Pancancer Analysis

Apobec3g Acts As A Therapeutic Target In Mesenchymal Gliomas By Sensitizing Cells To Radiation-Induced Cell Death

Immune Inactivation by APOBEC3B Enrichment Predicts Response to Chemotherapy and Survival in Gastric Cancer.

The Identification of APOBEC3G as a Potential Prognostic Biomarker in Acute Myeloid Leukemia and a Possible Drug Target for Crotonoside

APOBEC family reshapes the immune microenvironment and therapy sensitivity in clear cell renal cell carcinoma

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance

Comprehensive Bioinformatics Analyses of APOBECs Family and Identification of APOBEC3D As the Unfavorable Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.

Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types

Apobec3g Expression is Correlated with Poor Prognosis in Colon Carcinoma Patients with Hepatic Metastasis

Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas

ApoC1 promotes glioma metastasis by enhancing epithelial-mesenchymal transition and activating the STAT3 pathway

Regulation, functional impact, and therapeutic targeting of APOBEC3A in cancer

Dnar-16. Targeting Apobec Cytidine Deaminases To Enhance Radiosensitivity In Glioma

APOBEC Alteration Contributes to Tumor Growth and Immune Escape in Pan-Cancer

The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma

APOBEC3B Interaction with PRC2 Modulates Microenvironment to Promote HCC Progression.

APOBEC3G Expression Correlates with Unfavorable Prognosis and Immune Infiltration in Kidney Renal Clear Cell Carcinoma

Correlation of APOBEC3 in Tumor Tissues with Clinico-Pathological Features and Survival from Hepatocellular Carcinoma after Curative Hepatectomy.